Nasdaq OMX

Merus N.V.

Del

Merus to Participate in Upcoming Investor Conferences

UTRECHT, The Netherlands, 2016-08-31 13:00 CEST (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the Company will participate in the following upcoming investor conferences:

  • Ton Logtenberg, CEO, will present at the 2016 Credit Suisse Antibody Day on Wednesday, September 7 at 2:40 PM ET at Credit Suisse's offices at One Madison Avenue in New York City.
  • Management will participate in investor meetings at Citi’s 11thAnnual Biotech Conference on Thursday, September 8 at the Mandarin Oriental in Boston.

A live webcast of the Credit Suisse presentation will be available on the Investor page of the Company's website. An archived presentation will be available for 90 days.

About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics® are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have several of the same features of conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus' lead bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial in Europe as a potential treatment for HER2-expressing solid tumors. Merus' second bispecific antibody candidate, MCLA-117, is being developed as a potential treatment for acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, and Biclonics® designed to bind to various combinations of immunomodulatory molecules, including PD-1 and PD-L1.

Contacts:
Merus N.V.
Shelley Margetson - s.margetson@merus.nl
+31 (0)30 253 8800

Argot Partners
Kimberly Minarovich - kimberly@argotpartners.com
1-212-600-1902

Information om Nasdaq OMX

Nasdaq OMX
Nasdaq OMX
Nikolaj Plads 6
1007 København K

+45 3377 0377http://globenewswire.com